retatrutide and breastfeeding Contraindications: Risks Considerations for Patients image.cfm?name=04.jpg&id=906833

Description

Biermann noted that the dosing frequency he and his colleague studied in their clinical investigation was not the same as microdosing, a practice popularized by some celebrities and social media influencers that involves taking a smaller-than-recommended amount of the treatment

We conducted subgroup analyses based on prespecified risk factors, including age, sex, BMI, degree of liver fibrosis (FIB-4 score 1.3 among patients without cirrhosis), and diabetes severity (diabetes complications)

Studies show that GLP-1 drugs help reduce weight by improving satiety and decreasing cravings

In in-vitro and preclinical studies, it demonstrates notable effects on weight and glycemic indices, prompting further investigation into triple agonists that target GLP1, GIP, and glucagon receptors

The effects of incretin-based therapies on the brain are less well understood but there are a few findings that support the link between incretins and the brain